Lilly’s amyloid therapy not a big step forward from Biogen’s

With a more sophisticated protocol for selecting patients and positive Phase II data in hand, Eli Lilly is heading into a confirmatory trial of its Alzheimer’s therapy donanemab in an arguably stronger position than Biogen was in when it took aducanumab directly from Phase Ib into Phase III.

There’s little else to differentiate the two, based on the data released Monday.  ...